Market Place
Sourcing Support
OnKure to Present at Stifel 2024 Healthcare Conference
05 Nov 2024 //
GLOBENEWSWIRE
OnKure`s Data for OKI-219 at San Antonio Breast Cancer Symposium
01 Nov 2024 //
GLOBENEWSWIRE
OnKure Announces Merger And $65 Million Private Placement
04 Oct 2024 //
GLOBENEWSWIRE
OnKure Appoints Rogan Nunn As General Counsel And Secretary
19 Jun 2024 //
GLOBENEWSWIRE
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
13 May 2024 //
GLOBENEWSWIRE
OnKure hitches Reneo’s ride to Nasdaq, with $65M PIPE to boot
13 May 2024 //
FIERCE BIOTECH
OnKure Appoints Ann Howell, Pharm.D., as Vice President of Regulatory Affairs
20 Sep 2023 //
GLOBENEWSWIRE
OnKure Therapeutics Announces $54 Million Series C Financing
23 May 2023 //
GLOBENEWSWIRE
OnKure Therapeutics nabs $60M as HDAC inhibitor awaits solid-tumor readouts
04 Apr 2023 //
ENDPTS
OnKure Therapeutics Appoints Kevin S. Litwiler, Ph.D., as Senior Vice President
21 Jun 2022 //
GLOBENEWSWIRE
OnKure Begins Dosing in PIb/II Nautilus Trial of OKI-179 + Binimetinib
02 Jun 2022 //
GLOBENEWSWIRE
OnKure Therapeutics Expands Boulder Footprint with the Opening
25 Apr 2022 //
GLOBENEWSWIRE
OnKure Tx Announces Preclinical Data on OKI-179 in RAS-Mutated Tumor Models
08 Apr 2022 //
GLOBENEWSWIRE
OnKure Tx to Present Late-Breaking PC Data on OKI-179 at AACR
08 Mar 2022 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.